This research reveals challenges in implementing long-acting PrEP to improve HIV prevention in high-incidence populations, highlighting critical obstacles.
The introduction of long-acting antiviral prophylaxis drugs, exemplified by the twice-yearly injectable capsid inhibitor lenacapavir [1,2], marks a remarkable advance in HIV prevention, which address the adherence issue that has limited the real-world use of daily oral pre-exposure prophylaxis (PrEP) [3,4]. The long-acting formulations of lenacapavir offer a potent prevention tool, particularly well-suited for countries where the HIV transmission mainly occurred in certain populations with high incidence.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: